Share on LinkedInShare on LinkedIn

ARTICLE · 29 JANUARY 2026

Life Sciences In Canada: Year In Review 2025

Gowling WLG
Gowling WLG
Contributor
Gowling WLG

Gowling WLG

The firm The firm’s lawyers speak English, French, Russian and Ukrainian. The firm’s client base...

View firm profile
Explore more from Gowling WLG

The Canadian life science sector saw several significant developments in 2025. This article highlights key decisions, guidance, and regulatory changes that impacted the patent landscape.

CanadaIntellectual Property

The Canadian life science sector saw several significant developments in 2025. This article highlights key decisions, guidance, and regulatory changes that impacted the patent landscape.

1. Supreme Court of Canada hears arguments on validity of "methods of medical treatment"

On October 9, 2025, the Supreme Court of Canada heard arguments in Pharmascience Inc. v Janssen Inc., et al. (Supreme Court File No. 41209). A decision by the Supreme Court is expected in 2026.

At first instance before the Federal Court, Janssen's "335 Patent" was found to be valid and infringed. Pharmascience appealed on the sole issue that the claims of the 335 Patent at issue were invalid as claiming no patentable "method of medical treatment."

We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

See more popular content from